REDWOOD CITY, Calif.,
Aug. 20, 2018 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the use in medically supervised settings,
today announced that Dr. Pamela
Palmer, Chief Medical Officer, will be presenting at the
2018 Military Health System Research Symposium (MHSRS) on
August 20, 2018. The
presentation is entitled "Gender Differences in Safety and Efficacy
of the Sufentanil Sublingual Tablet 30 mcg for Treatment of
Moderate-to-Severe Acute Pain."
Details of the event are as follows:
MHSRS
Date: Monday, August 20,
2018
Location: Gaylord Palms Convention Center, Kissimmee, FL
Presentation Time: 4:15pm ET
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates in the
United States including DSUVIA™ (sufentanil sublingual
tablet, 30 mcg), with a proposed indication for the treatment of
moderate-to-severe acute pain in medically supervised settings, and
Zalviso® (sufentanil sublingual tablet system, 15 mcg) being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
hospitalized patients. DZUVEO™, as DSUVIA is known in
Europe, and Zalviso are both
approved products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-the-2018-military-health-system-research-symposium-300699277.html
SOURCE AcelRx Pharmaceuticals, Inc.